There is a new wave of pharma R&D spending happening globally - and particularly when it comes to companies in the US. While there is now limited scope for investing in R&D relating to generic medicines, due to the hot competition around these products, opportunities exist in many other areas, from specialist medicines to biologics. There are many US corporations that have the resources and facilities to focus on this in-house but others don't, which is why we are beginning to see a trend emerging in R&D spending towards outsourcing. R&D and manufacturing processes tend to have a lot of fixed costs, which is why they can be off-putting to handle internally and why there is now enthusiasm to invest in outsourcing them. As a result, companies that specialize in drug innovation and manufacturing are becoming increasingly popular - and this is where a sizable chunk of expanded pharma R&D spending is likely to end up this year.